CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
REVENUES:
Subscription and advertisement revenues	$ 288	$ 357	$ 631	$ 676
Royalties from product sales	86	117	286	274
Grant income	760	1,437	2,247	2,130
Sale of research products and services	132	98	176	188
Total revenues	1,266	2,009	3,340	3,268
Cost of sales	(95)	(260)	(320)	(525)
Gross Profit	1,171	1,749	3,020	2,743
OPERATING EXPENSES:
Research and development	(8,938)	(9,059)	(22,671)	(18,383)
General and administrative	(6,636)	(6,186)	(18,509)	(11,365)
Total operating expenses	(15,574)	(15,245)	(41,180)	(29,748)
Loss from operations	(14,403)	(13,496)	(38,160)	(27,005)
OTHER INCOME/(EXPENSES):
Interest income/(expense), net	(76)	4	(88)	(79)
BioTime's share of losses in equity method investment in Ascendance	(98)	0	(333)	0
Gain on deconsolidation of Asterias (Note 3)	49,048	0	49,048	0
Loss on equity method investment in Asterias at fair value (Note 4)	(13,483)	0	(13,483)	0
Other income/(expense), net	237	225	363	35
Total other income/(expense), net	35,628	229	35,507	(44)
INCOME (LOSS) BEFORE INCOME TAX BENEFIT	21,225	(13,267)	(2,653)	(27,049)
Deferred income tax benefit	0	1,271	0	2,448
NET INCOME (LOSS)	21,225	(11,996)	(2,653)	(24,601)
Net loss attributable to non-controlling interest	3,324	2,305	10,091	4,736
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC.	24,549	(9,691)	7,438	(19,865)
Dividends on preferred shares	0	(52)	0	(52)
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ 24,549	$ (9,743)	$ 7,438	$ (19,917)
NET INCOME (LOSS) PER COMMON SHARE:
BASIC (in dollars per share)	$ 0.26	$ (0.12)	$ 0.08	$ (0.25)
DILUTED (in dollars per share)	$ 0.26	$ (0.12)	$ 0.08	$ (0.25)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING:
BASIC (in shares)	93,240	78,362	91,831	78,312
DILUTED (in shares)	95,801	78,362	95,360	78,312